Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up before the market opened on Friday . The stock had previously closed at $46.93, but opened at $50.7725. Zealand Pharma A/S shares last traded at $51.65, with a volume of 355 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZLDPF. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Trading Up 12.5%

The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 3.75 and a beta of 0.88. The business has a 50-day simple moving average of $49.83 and a two-hundred day simple moving average of $65.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. As a group, research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.